12,372 trials
Allergic Rhinitis
Primary: The Change From Baseline in Rhinoconjunctivitis Symptoms Score at 11 - 12 Months Between the Actively Treated Patients and the Placebo Treated. — -1.77; -1.83 units on a…
Contraception: Optional Applicator for Insertion of Vaginal Ring
Primary: Percentage of Participants With Successful Ring Insertion — 100; 100 Percentage of participants
Treatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients
Primary: Percentage of Participants P Aeruginosa-free After Completion of the First Treatment Cycle — 84.6; 24.0 Percentage of participants — p=<0.001
Liver Transplantation
Primary: Change From Baseline (Randomization) in Renal Function — -13.29; 1.05 mL/min/1.73m^2 — p=<0.0001
Osteoporosis · Chronic Kidney Disease
Primary: Percent Change in BMD at the Total Lumbar Spine From Baseline to Month 12 — 4.5; -0.3 percent change — p=<0.001
Chronic Constipation · Constipation
Primary: 9/12 Week Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder — 13; 24; 158; 129 participants — p=0.0264
Healthy Volunteers · Haemophilus Influenzae Type b, Prevention
Primary: Number of Participants With Adverse Events — 31 participants
Human Papillomavirus Infection
Primary: Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen — 1657.9; 1557.4; 2678.8; 1496.1 mMU/mL — p=<0.001
Anemia
Primary: Mean Change in Hemoglobin Concentration From Baseline to Evaluation Periods — -0.00; -0.11; -0.12 g/dL — p=<0.0001
Active Ulcerative Colitis · Remission of Ulcerative Colitis
Primary: Active Phase: Proportion of Active Subjects Achieving Overall Improvement — 64.1; 69.2 percentage of participants
Von Willebrand Disease
Primary: Percentage of Participants With Treatment Success for Treated Bleeding Episodes — 100.0 Percent of participants
Hypertension · Chronic Kidney Disease
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF) — -13.3; -15.5 millimeter(s) of…
Advanced Parkinson's Disease
Primary: Average Daily Normalized "Off" Time: Change From Baseline To The Final PEG-J Visit — 7.37; 2.72 hours — p=<0.001
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) — -0.99; -0.07 percentage of glycosylated haemoglobin
Primary Peritoneal Carcinoma · Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Overall Survival — 0.35; 0.34; 0.39; 0.34 Proportion of participants